InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,954.40
(
-0.17%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
84.00
(
0.54%
)
Bitcoin
57,411.12
(
-1.42%
)
Post# of 251670
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 194780

Wednesday, 11/18/2015 10:18:19 AM

Wednesday, November 18, 2015 10:18:19 AM

Post# of 251670
FDA reviewing NVS’ 351(k) submission for Neulasta FoB:

https://www.novartis.com/news/media-releases/regulatory-submission-sandoz-proposed-biosimilar-pegfilgrastim-accepted-fda

NVS seeks FDA approval of the FoB for all of Neulasta’s approved indications (as was the case with NVS’ Zarxio FoB for Neupogen).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up